Early aggressive treatment approaches for multiple sclerosis
A Simpson, EM Mowry, SD Newsome - Current treatment options in …, 2021 - Springer
Purpose of review This review presents a comprehensive analysis of the current high-
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …
Optimizing treatment success in multiple sclerosis
Despite important advances in the treatment of multiple sclerosis (MS) over recent years, the
introduction of several disease-modifying therapies (DMTs), the burden of progressive …
introduction of several disease-modifying therapies (DMTs), the burden of progressive …
Long‐term evolution of multiple sclerosis disability in the treatment era
University of California, San Francisco MS … - Annals of …, 2016 - Wiley Online Library
Objective To characterize the accrual of long‐term disability in a cohort of actively treated
multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance …
multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance …
Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings
Objective: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active
relapsing-remitting multiple sclerosis and inadequate response to prior therapy. Methods: In …
relapsing-remitting multiple sclerosis and inadequate response to prior therapy. Methods: In …
Treatment optimization in MS: Canadian MS Working Group updated recommendations
The Canadian Multiple Sclerosis Working Group (CMSWG) developed practical
recommendations in 2004 to assist clinicians in optimizing the use of disease-modifying …
recommendations in 2004 to assist clinicians in optimizing the use of disease-modifying …
[HTML][HTML] Optimizing therapy early in multiple sclerosis: an evidence-based view
Therapies that target the underlying pathology of multiple sclerosis (MS), including focal and
diffuse damage, may improve long-term disease control. Focal damage (inflammatory …
diffuse damage, may improve long-term disease control. Focal damage (inflammatory …
No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: Clinician and patient perspectives [Narrative Review]
SD Newsome, C Binns, UW Kaunzner, S Morgan… - Neurology and …, 2023 - Springer
The emergence of high-efficacy therapies for multiple sclerosis (MS), which target
inflammation more effectively than traditional disease-modifying therapies, has led to a shift …
inflammation more effectively than traditional disease-modifying therapies, has led to a shift …
The transition from first-line to second-line therapy in multiple sclerosis
J Doerr, F Paul - Current treatment options in neurology, 2015 - Springer
Opinion statement Sufficient control of disease activity in multiple sclerosis (MS) patients,
particularly in the early phase of the disease, is crucial for the prevention of an unfavorable …
particularly in the early phase of the disease, is crucial for the prevention of an unfavorable …
Managing multiple sclerosis: treatment initiation, modification, and sequencing
MS Freedman, D Selchen, A Prat… - Canadian Journal of …, 2018 - cambridge.org
Recent therapeutic advances in the management of multiple sclerosis (MS) have raised
questions about the selection of appropriate patient candidates for various treatments and, if …
questions about the selection of appropriate patient candidates for various treatments and, if …
Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?
A Mähler, S Mandel, M Lorenz, U Ruegg, EE Wanker… - EPMA Journal, 2013 - Springer
Neurodegenerative disorders show an increasing prevalence in a number of highly
developed countries. Often, these diseases require life-long treatment mostly with drugs …
developed countries. Often, these diseases require life-long treatment mostly with drugs …